Department of Radiation Oncology, Sheba Medical Center, Ramat-Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Shaare Zedek Medical Center, Jerusalem, Israel; Hadassah Medical School, The Hebrew University, Jerusalem, Israel.
Breast. 2020 Feb;49:70-73. doi: 10.1016/j.breast.2019.10.011. Epub 2019 Nov 6.
We recently showed that prophylactic breast irradiation (PBI) reduces the risk of contralateral breast cancer in BRCA mutation carriers undergoing treatment for early breast cancer. It has been suggested that Background Parenchymal Enhancement (BPE) may be a biomarker for increased risk of breast cancer.
For participants in the trial we reviewed the MRI prior to enrollment and following radiation treatment and scored the contralateral breast for BPE and density.
Significant reduction of BPE was more commonly noted following PBI (p = 0.011) compared to the control group.
Reduction of BPE by PBI may contribute to its prophylactic effect.
我们最近发现,对于接受早期乳腺癌治疗的 BRCA 基因突变携带者,预防性乳房照射(PBI)可降低对侧乳腺癌的风险。有人提出背景实质增强(BPE)可能是乳腺癌风险增加的生物标志物。
对于参与该试验的患者,我们在入组前和放射治疗后回顾了 MRI,并对双侧乳房的 BPE 和密度进行了评分。
与对照组相比,PBI 后 BPE 显著减少(p=0.011)。
PBI 减少 BPE 可能有助于其预防作用。